- Product Name:
- ROPIVACAINE MESYLATER
- 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-
- Product Categories:
- Mol File:
Ropivacaine Chemical Properties
- Melting point:
- D25 -82.0° (c = 2 in methanol)
- Boiling point:
- 410.2±45.0 °C(Predicted)
- 1.044±0.06 g/cm3(Predicted)
- 8.16(at 25℃)
- CAS DataBase Reference
- 84057-95-4(CAS DataBase Reference)
- Language:English Provider:Ropivacaine
Ropivacaine Usage And Synthesis
Naropin was launched in 1996 in Australia, Denmark, Finland, the Netherlands and Sweden as a local anesthetic. It can be prepared in a number of ways the most efficient involves a three step sequence beginning with L-pipecolic acid. This compound is the first one in this family to be produced as the pure (S)- enantiomer. The (R)-enantiomer has been shown to have cardiotoxic effects. Thus ropivicaine has less cardiovascular and CNS toxicity than bupivacaine. It is a Na channel blocker that is specific for affecting nerve fibers responsible for transmission of pain (Aδ and C) with no effect on fibers responsible for motor function (Aβ). Clinically, it has distinct advantages over bupivacaine. Its effects are slower in onset, less intense and have a shorter duration. This is a result of extensive metabolism in the liver to the 3-hydroxy isomer by CYPIA2 isoenzyme.
Ropivacaine HCl is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly. - See more at: http://www.selleckchem.com/products/ropivacaine-hcl.html#sthash.hTK3J8yF.dpuf
ChEBI: A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.
Narapin [as hydrochloride] (Astra).
Ropivacaine (Naropin) is a recently developed longacting amide-linked local anesthetic. Its duration of action is similar to that of bupivacaine, but it is slightly less potent and requires higher concentrations to achieve the same degree of block. Its primary advantage over bupivacaine is its lesser degree of cardiotoxicity.
The recognized increase in cardiotoxicity of one bupivacaineisomer led to the stereospecific production of ropivacaine asthe single “S” (-) enantiomer. Ropivacaine is the propylanalog of mepivacaine (methyl) and bupivacaine (butyl). ThepKa of the tertiary nitrogen is 8.1, and it displays the same degreeof protein binding as bupivacaine ( 94%). Althoughropivacaine has similar properties as bupivacaine, it displaysless cardiotoxicity. The shortened alkyl chain gives it approximatelyone third of the lipid solubility of bupivacaine.
Ropivacaine is a long-acting amide-type local anestheticwith inherent vasoconstrictor activities, so it does not requirethe use of additional vasoconstrictors. It is approved forepidural, nerve block, infiltration, and intrathecal anesthesia.
The metabolism of ropivacaine in human is mediated by hepatic CYP1A2 isozymes and, to a minor extent, by CYP3A4. The major metabolite is 3-hydroxyropivacaine, and the minor metabolite is (S)-2′,6′-pipecoloxylidide (a N-dealkylated product).
- 0712-2580635- ;0712-2580635
- (S)Ropivacaine Mesilate
- (S)Ropivacaine Mesilate
- ROPIVACAINE MSILATE
- Ropivacaine impurity G
- S-ropivacaine mesylate
- (S)-ROPIVACAINE MSILATE
- Ropivacaine hydrochloride,ROPIVACAINE HCL,ROPIVACAINE HYDROCHLORIDE MONOHYDRATE,(S)-ROPIVACAINE HYDROCHLORIDE,S-ROPIVACAINE HCL
- Propyl butyrate
- ROPIVACAINE MESYLATE
- Propyl gallate
- S-ROPIVACAINE HCL,(S)-ROPIVACAINE HYDROCHLORIDE,ROPIVACAINE HCL,Ropivacaine mesilate ,Ropivacaine hydrochloride